{"schema":"sb.node.v1","id":"sb:e/ec4e23787e34b3edd4fc7c17","kind":"entity","label":{"text":"iaslc","locale":"en"},"identity":{"anchor":"label:en:iaslc","strength":"label"},"asOf":{"knowledgeCutoff":"2026-10-10T19:00:35.865848+00:00","snapshot":"deploy b663cc8b34a8931137d702b8e11a6acd5fab341d"},"lens":{"kind":"public"},"build":{"plane":"projected","builtFrom":["entity_graph.slim.json","entity_receipts (deploy asset)","event_graph.json","truth_records (deploy asset)","corroborated_record.json"],"rule":"node-projection.entity@v1"},"standing":{"evidence":{"supporting":26,"separatePublishers":6,"basis":"documents that mention the subject and the outlets that carried them; a mention is evidence the referent is in use, not evidence about any claim","receiptsOnTopic":{"state":"measured","share":0.692,"named":18,"of":26,"basis":"documents whose own title or summary lead names the subject, over every counted document that mentions it anywhere (the entity graph's measurement); receipts are drawn from the former only"}},"admission":{"state":"provisional","reason":"entity graph provenance 'observed'; the node carries no promotion receipt in v1","policy":"EQ-PROMOTION (receipt not carried)"},"disposition":{"state":"served","reason":"public record"},"validity":{"from":"2026-09-12","to":"2026-10-06","basis":"first and last day we saw it mentioned; not the subject's own lifetime"},"measurement":{"state":"partial","blind":["assertion coverage 0.077: about 92% of mentions carry no typed assertion"]}},"dimensions":{"domains":["society_news"],"activeDays":14,"assertions":{}},"up":[],"upNote":"An entity is a root: it is contained by nothing. Pan out by following R.","children":{"count":12,"byKind":{"observation":12},"items":[{"id":"sb:o/48297b9787295f935dbb70d2","kind":"observation","label":"Inside Precision Medicine · 2026-09-17 · IASLC Tumor Budding Grade Identifies High-Risk Lung Squamous Cell Carcinoma Patients","url":"https://www.insideprecisionmedicine.com/topics/oncology/iaslc-tumor-budding-grade-identifies-high-risk-lung-squamous-cell-carcinoma-patients/"},{"id":"sb:o/693376a645fb4fe7ae8fe642","kind":"observation","label":"PR Newswire · 2026-09-12 · International Association for the Study of Lung Cancer Launches Complimentary IASLC Full Membership for Eligible Countries to Expand Worldwide Participation in Thoracic Onc…","url":"https://www.prnewswire.com/news-releases/international-association-for-the-study-of-lung-cancer-launches-complimentary-iaslc-full-membership-for-eligible-countries-to-expand-worldwide-participation-in-thoracic-oncology-302876825.html"},{"id":"sb:o/cba7cb59d47de4aa75260817","kind":"observation","label":"The ASCO Post · 2026-10-06 · Extensive-Stage SCLC Subcutaneous Tarlatamab","url":"https://ascopost.com/videos/iaslc-wclc-2026/extensive-stage-sclc-subcutaneous-tarlatamab/"},{"id":"sb:o/cc6e4750cc495c9cf9a0e942","kind":"observation","label":"The ASCO Post · 2026-10-05 · Relapsed or Refractory SCLC Phase I Study of Novel CAR T-Cell Therapy","url":"https://ascopost.com/videos/iaslc-wclc-2026/relapsed-or-refractory-sclc-phase-i-study-of-novel-car-t-cell-therapy/"},{"id":"sb:o/e734daadfcc0da8e4ceb739f","kind":"observation","label":"The ASCO Post · 2026-10-05 · Metastatic PD-L1–High NSCLC Sacituzumab Govitecan/Pembrolizumab","url":"https://ascopost.com/videos/iaslc-wclc-2026/metastatic-pd-l1-high-nsclc-sacituzumab-govitecanpembrolizumab/"},{"id":"sb:o/901df94790a9c91573864ae0","kind":"observation","label":"The ASCO Post · 2026-10-02 · Advanced Lung Cancer Pumitamig Plus Elfetabart Drozuntecan","url":"https://ascopost.com/videos/iaslc-wclc-2026/advanced-lung-cancer-pumitamig-plus-elfetabart-drozuntecan/"},{"id":"sb:o/e7f192ca5c1a7ae7fcc55b5d","kind":"observation","label":"The ASCO Post · 2026-09-30 · Targeting B7-H3 in Second-Line SCLC Treatment Novel ADCs","url":"https://ascopost.com/videos/iaslc-wclc-2026/targeting-b7-h3-in-second-line-sclc-treatment-novel-adcs/"},{"id":"sb:o/872fe75bc02707fa00730ce2","kind":"observation","label":"The ASCO Post · 2026-09-29 · Mobile Lung CT Screening in Resource-Limited Settings BRELT3","url":"https://ascopost.com/videos/iaslc-wclc-2026/mobile-lung-ct-screening-in-resource-limited-settings-brelt3/"},{"id":"sb:o/d531ca6fb144412999cfbcf3","kind":"observation","label":"The ASCO Post · 2026-09-24 · SCLC Tarlatamab Extended-Interval Dosing Regimens","url":"https://ascopost.com/videos/iaslc-wclc-2026/sclc-tarlatamab-extended-interval-dosing-regimens/"},{"id":"sb:o/fd54375928c464aee95c5da4","kind":"observation","label":"The ASCO Post · 2026-09-22 · Metastatic HER2-Mutant NSCLC First-Line T-DXd","url":"https://ascopost.com/videos/iaslc-wclc-2026/metastatic-her2-mutant-nsclc-first-line-t-dxd/"}],"cursor":"c1.eyJpZCI6InNiOmUvZWM0ZTIzNzg3ZTM0YjNlZGQ0ZmM3YzE3IiwibCI6ImNoaWxkcmVuIiwibyI6MTAsImsiOm51bGwsImEiOiIyMDI2LTEwLTEwVDE5OjAwOjM1Ljg2NTg0OCswMDowMCJ9","order":"newest first; we keep the 12 newest receipts for this entity whose own title or summary lead (the entity graph's test) names it. Its other observations are counted in standing.evidence.supporting but are not addressable in v1"},"relations":{"count":10,"byKind":{"co-mentioned":10},"items":[{"kind":"relation","label":"co-mentioned with lung cancer (26 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/1d62b43fc012d61224265153"},{"kind":"relation","label":"co-mentioned with wclc (24 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/9de40777dc0e4eb43fcff74f"},{"kind":"relation","label":"co-mentioned with egfr (15 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/da8f6a66a77f16a6f36c47c5"},{"kind":"relation","label":"co-mentioned with cancer center (14 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/d9fba223284ca43f6603893c"},{"kind":"relation","label":"co-mentioned with international association (13 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/36f8a223d742212c02e1d2ca"},{"kind":"relation","label":"co-mentioned with egfr-mutated (12 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/278fcab99990589ccb198e47"},{"kind":"relation","label":"co-mentioned with iiib (12 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/c740b3dcf4f8c66aaa0dae86"},{"kind":"relation","label":"co-mentioned with dana-farber cancer institute (11 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/57f422c0d1ebfec712217a82"},{"kind":"relation","label":"co-mentioned with her2-mutant (10 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/b53962e64feb3468d468a455"},{"kind":"relation","label":"co-mentioned with her3 (10 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/38650927c2b4d388efd1b6a0"}],"cursor":null,"order":"situations first, then claims (the subject's own maintained record, then site-wide corroborated clusters; each label ends with its standing), then co-mentions by shared documents, descending. Co-mentions are the ten strongest the entity graph keeps per entity"},"edge":{"state":"continues"},"links":{"rest":"/api/v1/node/e/ec4e23787e34b3edd4fc7c17","mcp":"traverse {\"id\":\"sb:e/ec4e23787e34b3edd4fc7c17\"}","page":"/entity/iaslc/"},"limits":{"levelsPerCall":1,"pageSize":10,"maxPageSize":50,"membersMax":50,"statement":"One level per call: depth is 1 and only 1, and there is no whole-graph dump. pageSize 1-50 (default 10); a page limit is a cursor, never an edge. Members are listed up to 50. At most 60 traverse calls a minute per caller (runaway-loop protection, not a meter). One knowledge cutoff is served: the deploy's."},"actions":[{"verb":"unfold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/ec4e23787e34b3edd4fc7c17\",\"level\":\"children\"}"},{"verb":"fold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/ec4e23787e34b3edd4fc7c17\"}"},{"verb":"panOut","lit":false,"effect":"read","layer":"cantina","reason":"An entity is a root: it is contained by nothing. Pan out by following R."},{"verb":"follow","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/ec4e23787e34b3edd4fc7c17\",\"level\":\"relations\"}"},{"verb":"receipts","lit":false,"effect":"read","layer":"cantina","reason":"receipts are the observations below this node; unfold to reach them"},{"verb":"edge","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/ec4e23787e34b3edd4fc7c17\"}"},{"verb":"asOf","lit":false,"effect":"read","layer":"cantina","reason":"v1 serves one knowledge cutoff, this deploy's; walking an earlier cutoff needs retained history (EQ-REPLAY), which v1 does not keep"},{"verb":"switchObserver","lit":false,"effect":"read","layer":"cantina","reason":"the public record is the same for every observer; traversal through a Watch's lens is not served in v1"},{"verb":"readOriginal","lit":false,"effect":"read","layer":"cantina","reason":"no translation is applied on this node; every label is the source's own text"},{"verb":"save","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"saving applies to a configured Watch; configure one around this node first (free), then save it"},{"verb":"deliver","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"delivery applies to a saved Watch"},{"verb":"format","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"output format applies to a saved Watch"},{"verb":"deltaR","lit":false,"effect":"read","layer":"workshop","reason":"Delta R needs a saved Watch with a previous reading"},{"verb":"read","lit":false,"effect":"read","layer":"docking-bay","reason":"one-time Reads are parked until the Commander decides their shape (#938)"}]}